Sankyo's Antihypertensive Agent, ARB Olmesartan to Be Available in Central and South America.
Tokyo, Japan, Aug 8, 2005 - (JCNN) - Sankyo announced on August 5 that it has signed a licensing agreement with Schering-Plough for its proprietary antihypertensive agent, olmesartan, an angiotensin II receptor blocker.Under the terms of the agreement, Schering-Plough will exclusively sell the agent in Argentina, Boilvia, Chile, Paraguay, Peru and Uruguay.
In addition, Sankyo will allow Schering-Plough to co-market the agent in Costa Rica, the Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama and Venezuela.
Olmesartan is currently marketed in about 30 countries around the world.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
![]() ![]() ![]() ![]() | |
Publication: | JCNN News Summaries |
---|---|
Geographic Code: | 1USA |
Date: | Aug 9, 2005 |
Words: | 103 |
Previous Article: | Ivy Cosmetics, Kitasato University Jointly Confirm That Shellac May Combat Skin Disorders. |
Next Article: | Nippon Organon to Release Recombinant Follicle Stimulating Hormone Follistim. |
Topics: |